Role of heregulin in human cancer

Breuleux, M.
September 2007
Cellular & Molecular Life Sciences;Sep2007, Vol. 64 Issue 18, p2358
Academic Journal
Heregulin (HRG) is a soluble secreted growth factor, which, upon binding and activation of ErbB3 and ErbB4 transmembrane receptor tyrosine kinases, is involved in cell proliferation, invasion, survival and differentiation of normal and malignant tissues. The HRG gene family consists of four members: HRG-1, HRG-2, HRG-3 and HRG-4, of which a multitude of different isoforms are synthesized by alternative exon splicing, showing various tissue distribution and biological activities. Disruption of the physiological balance between HRG ligands and their ErbB receptors is implicated in the formation of a variety of human cancers. The general mechanisms involved in HRG-induced tumorigenesis is discussed.


Related Articles

  • Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts. Bozec, A.; Formento, P.; Lassalle, S.; Lippens, C.; Hofman, P.; Milano, G. // British Journal of Cancer;7/2/2007, Vol. 97 Issue 1, p65 

    The aim of this study was to investigate the effects of combining antiangiogenic treatment, epidermal growth factor receptor (EGFR) targeting and irradiation (RT). We evaluated AZD2171, a highly potent, orally active, vascular endothelial growth factor (VEGF) signalling inhibitor, gefitinib, an...

  • Spleen Tyrosine Kinase Modulates the Proliferation and Phenotypes of Vascular Smooth Muscle Cells Induced by Platelet-Derived Growth Factor. Zhengxiang Gao; Lili Cao; Qin Luo; Xiaoshuang Wang; Li Yu; Tao Wang; Hanmin Liu // DNA & Cell Biology;Mar2011, Vol. 30 Issue 3, p149 

    Platelet-derived growth factor BB (PDGF-BB) regulates vascular smooth muscle cells (VSMCs) by activating signaling cascades that promote vasoconstriction and growth, but the underlying mechanisms remain incompletely characterized. In this study, we aimed at investigating the role of spleen...

  • AXL regulates mesothelioma proliferation and invasiveness. Ou, W-B; Corson, J M; Flynn, D L; Lu, W-P; Wise, S C; Bueno, R; Sugarbaker, D J; Fletcher, J A // Oncogene;4/7/2011, Vol. 30 Issue 14, p1643 

    Mesothelioma is an asbestos-associated and notoriously chemotherapy-resistant neoplasm. Activation of the receptor tyrosine kinases (RTKs), epidermal growth factor receptor and MET, has been described in subsets of mesothelioma, suggesting that TKs might represent therapeutic targets in this...

  • Review of Clinic Trials: Agents Targeting c-Met. Abidoye, Oyewale; Murukurthy, Nadh; Salgia, Ravi // Reviews on Recent Clinical Trials;May2007, Vol. 2 Issue 2, p143 

    Receptor tyrosine kinases are a group of molecules that can enhance cellular proliferation, cell motility and migration, and eventual metastasis. c-Met receptor tyrosine kinase has a significant biological and biochemical effect on cancer cells, and appears to be an important therapeutic target....

  • The Role of Cetuximab and Other Epidermal Growth Factor Receptor Monoclonal Antibodies in the Treatment of Advanced Non-Small Cell Lung Cancer. Rossi, Antonio; Bria, Emilio; Maione, Paolo; Palazzolo, Giovanni; Falanga, Marzia; Gridelli, Cesare // Reviews on Recent Clinical Trials;Sep2008, Vol. 3 Issue 3, p217 

    Lung cancer continues to be the leading cause of cancer-related deaths in the western civilization and developing countries. Non-small cell lung cancer (NSCLC) accounts for > 85% of all cases of lung cancer. Since most patients with NSCLC have advanced disease at diagnosis, to date chemotherapy...

  • Tyrosine Kinases as Targets for Anti-Inflammatory Therapy. Tamura, Teruko; Koch, Alexandra // Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry;Feb2007, Vol. 6 Issue 1, p47 

    Tyrosine kinases play key roles in cell proliferation, differentiation, survival, cell migration, tissue development, and cell metabolisms. Mutation and /or truncation in tyrosine kinases result in their constitutive activation independent of ligand stimulation. The constitutively activated...

  • Ectodomain shedding and remnant peptide signalling of EGFRs and their ligands. Higashiyama, Shigeki; Nanba, Daisuke; Nakayama, Hironao; Inoue, Hirofumi; Fukuda, Shinji // Journal of Biochemistry;Jul2011, Vol. 150 Issue 1, p15 

    Both receptor tyrosine kinases epidermal growth factor receptors (EGFRs) and their ligands are transmembrane proteins. It has been known that ligand binding activates cytoplasmic tyrosine kinase domains of EGFRs, resulting in the transduction of signals for cell proliferation, migration,...

  • Tyrosine Kinase Inhibitors in Thyroid Cancer: May Axl/Gas6 Pathway be a Hidden Target? Mehlika ISILDAK, S.; TUTUNCU, Neslihan B.; ALTUNDAG, Ozden // International Journal of Hematology & Oncology / UHOD: Uluslarar;2013, Vol. 23 Issue 3, p207 

    Tyrosine kinase inhibitors are molecules that block various intracellular signaling pathways. Trials with some tyrosine kinase inhibitors showed promising results in thyroid cancer. They are thought to owe their antitumor property mainly to their effect on vascular endothelial growth factor...

  • Feedback inhibition by RALT controls signal output by the ErbB network. Anastasi, Sergio; Fiorentino, Loredana; Fiorini, Monia; Fraioli, Rocco; Sala, Gianluca; Castellani, L; Alema, Stefano; Alimandi, Maurizio; Segatto, Oreste // Oncogene;7/3/2003, Vol. 22 Issue 27, p4221 

    The ErbB-2 interacting protein receptor-associated late transducer (RALT) was previously identified as a feedback inhibitor of ErbB-2 mitogenic signals. We now report that RALT binds to ligand-activated epidermal growth factor receptor (EGFR), ErbB-4 and ErbB-2.ErbB-3 dimers. When ectopically...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics